logo
Share SHARE
FONT-SIZE Plus   Neg

Theravance, Clinigen Ink Commercialization Agreement In EU For VIBATIV

Clinigen Group plc (CLIN.L) and Theravance Inc. (THRX) have reached an exclusive commercialization agreement in the European Union or EU and certain other countries in Europe for VIBATIV to treat nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus or MRSA when other alternatives are not suitable.

VIBATIV is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

According to the deal, Theravance has granted Clinigen exclusive commercialization rights to VIBATIV in the EU and some other European countries, including Switzerland and Norway. Theravance, in turn, would receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Hyundai Motor America, an official NFL sponsor, is returning to Super Bowl advertising, and planning to shoot a documentary as the game is being played to run in its spot. The reigning 2016 USA Today Super Bowl Ad Meter winner, in a statement on Wednesday, said it will film a 90-second documentary during the game that will capture some of the best off-the-field Super Bowl moments. Consumer Financial Protection Bureau or CFPB filed a lawsuit Wednesday against Navient, the nation's largest student loan company, alleging that it failed borrowers at at every stage of repayment. In response, Navient, in a statement, said the allegations are unfounded, and with political motivations, and rejected CFPB ultimatum to settle by Inauguration Day or be sued. Lilly is all set to acquire CoLucid Pharma for $46.50 per share in cash or approximately $960 million.
comments powered by Disqus
Follow RTT